Stifel Nicolaus analyst Stephen Willey reiterated a Hold rating on Akcea Therapeutics Inc (NASDAQ: AKCA) yesterday and set a price target of $33. The company’s shares closed yesterday at $34.19, close to its 52-week high of $38.06.
According to TipRanks.com, Willey is a 5-star analyst with an average return of 21.5% and a 50.7% success rate. Willey covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Lexicon Pharmaceuticals, and Spark Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Akcea Therapeutics Inc with a $35.33 average price target.
See today’s analyst top recommended stocks >>
Based on Akcea Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $62.05 million. In comparison, last year the company had a GAAP net loss of $11.94 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akcea Therapeutics, Inc. is a late-stage pharmaceutical company, which engages in the development and commercializing of drugs fro the treatment of cardio metabolic diseases caused by lipid disorders. Its products include novel drugs under the followng brands: volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx.
